Evaluation of pharmacological treatment strategies in traumatic brain injury

Niklas Marklund, Asha Bakshi, Deborah J. Castelbuono, Valeria Conte, Tracy K. McIntosh

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a devastating disease, predominantely affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.

Original languageEnglish
Pages (from-to)1645-1680
Number of pages36
JournalCurrent Pharmaceutical Design
Volume12
Issue number13
DOIs
Publication statusPublished - May 2006

Fingerprint

Pharmacology
Therapeutics
Traumatic Brain Injury
Survivors
Theoretical Models
Quality of Life
Clinical Trials
Brain
Pharmaceutical Preparations

Keywords

  • Pharmacology
  • Traumatic brain injury

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Evaluation of pharmacological treatment strategies in traumatic brain injury. / Marklund, Niklas; Bakshi, Asha; Castelbuono, Deborah J.; Conte, Valeria; McIntosh, Tracy K.

In: Current Pharmaceutical Design, Vol. 12, No. 13, 05.2006, p. 1645-1680.

Research output: Contribution to journalArticle

Marklund, Niklas ; Bakshi, Asha ; Castelbuono, Deborah J. ; Conte, Valeria ; McIntosh, Tracy K. / Evaluation of pharmacological treatment strategies in traumatic brain injury. In: Current Pharmaceutical Design. 2006 ; Vol. 12, No. 13. pp. 1645-1680.
@article{ecc2f72a42d249cfb7859baba4628922,
title = "Evaluation of pharmacological treatment strategies in traumatic brain injury",
abstract = "Traumatic brain injury (TBI) is a devastating disease, predominantely affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.",
keywords = "Pharmacology, Traumatic brain injury",
author = "Niklas Marklund and Asha Bakshi and Castelbuono, {Deborah J.} and Valeria Conte and McIntosh, {Tracy K.}",
year = "2006",
month = "5",
doi = "10.2174/138161206776843340",
language = "English",
volume = "12",
pages = "1645--1680",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Evaluation of pharmacological treatment strategies in traumatic brain injury

AU - Marklund, Niklas

AU - Bakshi, Asha

AU - Castelbuono, Deborah J.

AU - Conte, Valeria

AU - McIntosh, Tracy K.

PY - 2006/5

Y1 - 2006/5

N2 - Traumatic brain injury (TBI) is a devastating disease, predominantely affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.

AB - Traumatic brain injury (TBI) is a devastating disease, predominantely affecting young people. Although the prognosis for TBI victims has improved in recent years, many survivors of TBI suffer from emotional, cognitive and motor disturbances and a decreased quality of life. In recent years, there has been a rapid increase in the number of pharmacological targets evaluated in clinically-relevant experimental TBI models, showing improved cognitive and motor outcome and decreased loss of brain tissue. Despite the completion of several recent clinical trials using compounds showing neuroprotection in preclinical studies, pharmaceutical treatment strategies with proven clinical benefit are still lacking. This paper reviews the preclinical pharmacological treatment studies evaluated to date in experimental models of TBI. Although human TBI is a complex and multifaceted disease, these studies provide encouraging translational data suggesting that pharmacological compounds, delivered in a clinically-relevant time window, may improve the outcome of TBI patients.

KW - Pharmacology

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=33646516853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646516853&partnerID=8YFLogxK

U2 - 10.2174/138161206776843340

DO - 10.2174/138161206776843340

M3 - Article

C2 - 16729876

AN - SCOPUS:33646516853

VL - 12

SP - 1645

EP - 1680

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 13

ER -